Who can sue the FDA? Answering Justice Alito’s question from the mifepristone arguments; The U.S. needs a bipartisan industrial policy for the life sciences

Taking stock of the drug industry, from the lab to the medicine chest

March 29, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe Who can sue the FDA? Answering Justice Alito's question from the mifepristone arguments Justice Samuel Alito had a question at the arguments over mifepristone: If the doctors who brought that case can't sue the FDA over a drug's label, who can? By Sarah Owermohle Opinion: The U.S. needs a bipartisan industrial policy for the life sciences President Biden's efforts to revitalize the nation's technology-based industries should include industrial policy for the life sciences. By James C. Robinson Why researchers think human milk could repair the gut microbiome and reduce infections Researchers say oligosaccharides, or sugars in human milk, could help repair gut microbiome and boost immunity in immunocompromised patients. By Deborah Balthazar

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser